ClinicalTrials.gg
RecruitingNCT07474571Updated Mar 19, 2026

Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging

An observational study in Osteoarthitis and Osteoporosis, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Peking University People's Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2005; still recruiting 21 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
13th of 30
2,000 · median 1,750
Started
2005
with 1 other
Observational
30 of 87
12 open now
Primary completion
2026-12
later than 21 of 32 live
Registered
81st of 87
by date
Lead sponsor
2 of 87
Peking University People's Hospital

Among the 87 studies in Osteoporosis with a site in China, this one is the 13th largest by planned enrollment of the 30 observational ones that give a count, is one of 2 that started in 2005, is one of 30 observational ones, reaches primary completion later than 21 of the 32 other live ones, and was the 81st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

Study Overview This clinical research focuses on the development and validation of a multimodal artificial intelligence (AI) platform designed for the automated diagnosis and precise staging of two major musculoskeletal conditions: Osteoporosis (OP) and Osteoarthritis (OA). By integrating diverse clinical imaging data, the study aims to provide a more objective and standardized approach to assessing bone and joint degeneration.

Technological Core: Intelligent Staging

Traditional diagnosis often relies on manual interpretation, which can lead to inter-observer variability. This study employs deep learning and multimodal imaging to:

For Osteoporosis: Automatically quantify bone mineral density and micro-architectural changes to determine the stage of bone loss and evaluate fracture risk.

For Osteoarthritis: Identify subtle radiological markers such as joint space narrowing and osteophyte formation to categorize the severity of joint degeneration according to international staging standards (e.g., Kellgren-Lawrence scale).

Why This Matters Early Intervention: By identifying early-stage changes in bone density and joint integrity, clinicians can implement preventive treatments before significant disability occurs.

Standardized Care: The intelligent diagnostic model provides a "digital second opinion," ensuring consistent staging across different healthcare settings.

Efficiency: The automated workflow reduces the workload of radiologists while maintaining high diagnostic accuracy.

Ethical Compliance The study is conducted at Peking University People's Hospital under the supervision of the Institutional Review Board (Approval No. 2026PHB097-001). It strictly adheres to international ethical standards, including the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines, to ensure patient data privacy and safety.

Read the detailed description
  1. Research Rationale and Goals Musculoskeletal aging often presents as a complex interplay between Osteoporosis (OP) and Osteoarthritis (OA). Despite their prevalence, current diagnostic workflows frequently treat these conditions in isolation, often relying on manual radiological staging that is prone to inter-observer variability. This study aims to develop and validate a multimodal artificial intelligence (AI) platform capable of simultaneous detection and precise disease staging for both OP and OA. By integrating diverse data sources-including clinical laboratory markers, patient history, and multiple imaging modalities (X-ray, CT, and MRI)-the project seeks to provide a holistic and objective assessment of skeletal health.
  2. Study Design and Population The research employs a bidirectional observational cohort study design. Retrospective Cohort (Model Development): Data will be collected from approximately 1,500 patients who visited the Peking University People's Hospital (PKUPH) between November 2005 and November 2025.

    Prospective Cohort (External Validation): At least 500 new participants will be recruited starting from December 2025 to test the model's performance in a real-world clinical setting.

    The study targets adults aged 18 to 90 who have completed relevant musculoskeletal imaging scans.

  3. Methodology and AI PipelineThe study is divided into three strategic phases:Phase I: Multimodal Data Integration: Collection of de-identified imaging (X-ray/CT/MR), laboratory indices (e.g., bone turnover markers, calcium-phosphorus metabolism), and clinical demographics (Age, BMI, medical history).Phase II: Intelligent Diagnostic Staging: Leveraging Convolutional Neural Networks (CNN) for image feature extraction and machine learning algorithms (e.g., XGBoost, SVM) for clinical feature fusion.For Osteoporosis: The model will categorize bone health stages (Normal, Osteopenia, Osteoporosis) using DXA T-scores as the gold standard.For Osteoarthritis: The system will automate grading based on the Kellgren-Lawrence (KL) scale, identifying joint space narrowing and osteophytic progression.Phase III: Validation and Explainability: Internal cross-validation and independent external testing using the prospective cohort. SHAP (Shapley Additive Explanations) analysis will be applied to quantify the contribution of each modality to the final diagnostic decision, ensuring clinical transparency.
  4. Outcome Measures The primary outcome is the diagnostic accuracy (AUC, Sensitivity, Specificity) of the AI model for both conditions. Secondary outcomes focus on long-term clinical utility, including the incidence of new fragility fractures and changes in functional scores (e.g., VAS or OKS) during the follow-up periods (6, 12, 24, and 36 months).
  5. Ethical Oversight and Data Safety The study is conducted at Peking University People's Hospital under the approval of the Institutional Review Board (Approval No. 2026PHB097-001). It adheres to GCP principles and the Declaration of Helsinki. All imaging and clinical data are strictly de-identified (anonymized) before being entered into the secure, encrypted research database to protect patient privacy.
03

Conditions studied

  • Osteoarthitis
  • Osteoporosis

Keywords

  • artificial intelligence
  • osteoarthitis
  • diagnosis
  • machine learning
  • osteoporosis
  • clinical images
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study Population DescriptionThe study population consists of adult patients seeking medical consultation or treatment at the Department of Orthopaedic Trauma, Peking University People's Hospital. This population represents a diverse clinical spectrum of musculoskeletal aging, ranging from healthy skeletal status to various stages of Osteoporosis (OP) and Osteoarthritis (OA).The research employs a bidirectional cohort structure:Retrospective Cohort: Includes approximately 1,500 patients treated between November 2005 and November 2025, primarily used for model training and internal algorithm validation.Prospective Cohort: Includes at least 500 patients recruited starting from December 2025, used for independent external validation of the model's diagnostic accuracy and staging robustness in a real-world clinical setting.Participants are characterized by their availability of multimodal data, including radiological images (X-ray, CT, MRI) and clinical laboratory indicators (e.g., bone tur

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Adults aged at least 18 years.
  • Gender: No gender restrictions; both male and female participants are eligible.
  • Imaging Data: Participants must have completed relevant clinical imaging scans of skeletal sites, including but not limited to X-ray, CT (plain scan), or MRI (plain scan).
  • Anatomical Integrity: The skeletal structure of the target area must be free from congenital or acquired deformities.
  • Absence of Implants: No internal fixation materials or orthopedic implants in the skeletal areas being assessed.

Exclusion criteria

Exclusion Criteria:

  • Pathological History: Patients with a history of prior pathological fractures.
  • : Patients seeking treatment or diagnosed with bone tumors or other systemic malignancies.
  • Medication History: Patients with a history of long-term use, which may significantly affect bone density and joint structure.
  • Recent Treatment: Patients who have undergone radiotherapy or chemotherapy within the past six months.
  • Data Quality: Patients whose imaging data is of insufficient quality for AI analysis or lacks clear clinical diagnostic "gold standard" references (e.g., missing DXA results for osteoporosis staging).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Peking University People's Hospital cohort 1

    participants with osteoarthritis

    Other: No Interventions

  • Peking University People's Hospital cohort 2

    participants with osteoporosis

    Other: No Interventions

  • Sun yat-sen memorial hospital 1

    participants with osteoarthritis

    Other: No Interventions

  • Sun yat-sen memorial hospital 2

    participants with osteoporosis

    Other: No Interventions

  • Peking University People's Hospital cohort 3

    participants without osteoporosis and osteoarthritis

    Other: No Interventions

  • Sun yat-sen memorial hospital 3

    participants without osteoporosis and osteoarthritis

    Other: No Interventions

Interventions

  • OtherNo Interventions

    No Interventions

06

What researchers measure

Primary outcomes

  1. Bone age status

    Bone mineral density and osteoarthitis

    Time frame: From enrollment to the initial treatment at 2 years

07

Study locations

1 of 1 sites recruiting
  • Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Privacy and Confidentiality Risks: The study involves sensitive clinical imaging (X-ray, CT, MRI) and laboratory data from patients at Peking University People's Hospital. Even after de-identification, there is a risk that high-resolution medical images could be re-identified, violating patient privacy agreements .Institutional Data Policy: The protocol states that data processing and export are restricted to computers registered within the hospital, and "data does not leave the hospital". This strict internal data management policy is designed to maintain security and hospital-level control over clinical assets.Ethical Constraints: The Institutional Review Board (IRB) approved the study based on strict data protection measures. Sharing raw IPD externally might require additional informed consent from participants or further ethical amendments that were not part of the original approval (2026PHB097-001).Intellectual Property and Proprietary Algorithms: Since this study involves

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2005 (actual). Primary completion is estimated for Dec 2026, 253 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 16, 2026
StartActual
Nov 1, 2005
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07474571
Responsible party
Yuhui Kou (Research Fellow, Assistant to the Department of Orthopaedic Trauma, Peking University People's Hospital) — Principal investigator
First posted
Mar 16, 2026
Start date
Nov 1, 2005
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Yuhui Kou, M.D
Contact
yuhuikou@bjmu.edu.cn
13146213332

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion